Quantcast

Latest Sangamo BioSciences Inc. Stories

2014-07-16 16:23:59

RICHMOND, Calif., July 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its second quarter 2014 financial results after the market closes on Wednesday, July 23, 2014. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other new business...

2014-06-19 08:28:26

RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms. Parker, who founded and served as President and CEO of Targeted Genetics Corporation, brings more than 30 years of experience in the biotechnology industry, including 16 years of specific experience in cell and gene therapy. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO "We are very pleased to...

2014-06-17 16:26:14

RICHMOND, Calif., June 17, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Philip Gregory, D.Phil., Sangamo's senior vice president of research and CSO, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at 3:30 pm ET on Tuesday, June 24, 2014, at the 9th Annual JMP Securities Healthcare Conference. The conference is being held in New York....

2014-05-30 08:24:46

First Clinical Application of Genome Editing Technology in Hematopoietic Stem/Progenitor Cells RICHMOND, Calif., May 30, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN)...

2014-05-29 20:23:00

RICHMOND, Calif., May 29, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at 1:00 pm ET on Thursday, June 5, 2014, at the Jefferies 2014 Global Healthcare Conference which will be held in New York. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO The...

2014-05-28 16:26:41

Groundbreaking Nature Publication Describes Successful ZFN Driven Genome Editing in Long-Term Repopulating Stem Cells Necessary for Clinical Translation RICHMOND, Calif., May 28, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in Nature of data demonstrating efficient zinc finger nuclease (ZFN)-mediated, targeted gene insertion that resulted in correction of the genetic defect in stem cells from an individual with X-linked severe combined...

2014-05-27 08:28:00

SB-728-T-Treated Subject Maintains Control of Viral Load for 45 Weeks Without Anti-Retroviral Drugs RICHMOND, Calif., May 27, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) were outlined in several presentations and posters at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) from May 21-24, 2014....

2014-05-15 16:28:38

RICHMOND, Calif., May 15, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at noon ET on Wednesday May 21, 2014, at the UBS Global Healthcare Conference which will be held in New York....

2014-05-14 08:31:21

RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) will be presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fourteen oral and poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs...

2014-05-06 16:32:43

Partnership with Biogen Idec and Recent Follow-on Financing Enhance Cash Position RICHMOND, Calif., May 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO For the first quarter ended March 31, 2014, Sangamo reported a consolidated net loss of $7.6 million, or $0.12 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related